U.S. Markets open in 5 hrs 7 mins

Drug Overdose - Pipeline Review, H2 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--

The "Drug Overdose - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 1, 3, 5, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

  • Nov 04, 2019: Adamis Pharmaceuticals provides regulatory update for its higher dose Naloxone Pre-Filled Syringe
  • Oct 08, 2019: Adamis Pharmaceuticals announces presentation of ZIMHI data at IHV Scientific Meeting
  • Sep 26, 2019: Adamis Pharmaceuticals announces presentation pertaining to its high dose naloxone product candidate at IHV Scientific Meeting
  • Sep 03, 2019: Adamis Pharmaceuticals provides update for Naloxone product candidate
  • Aug 07, 2019: Northwest Territories makes NARCAN (naloxone) nasal spray available to all residents for free of charge in response to the opioid crisis
  • Jul 03, 2019: FDA accepts new drug application for insys therapeutics naloxone nasal spray for the emergency treatment of known or suspected opioid overdose
  • Jun 27, 2019: Adamis Pharmaceuticals provides update on litigation with kaleo
  • Jun 11, 2019: Adamis Pharmaceuticals provides update on its higher dose Naloxone injection product
  • May 21, 2019: Adamis Pharmaceuticals announces patent litigation regarding its higher dose Naloxone Injection Product
  • May 14, 2019: Adamis Pharmaceuticals announces conditional acceptance by FDA of proprietary name for higher dose Naloxone product
  • Apr 08, 2019: Opiant Pharmaceuticals announces publication of clinical pharmacokinetic data supporting potential of OPNT003, nasal nalmefene, for treatment of synthetic opioid overdose
  • Apr 01, 2019: Study finds vast differences in ease-of-use for Naloxone delivery methods
  • Apr 01, 2019: Opiant Pharmaceuticals announces award of second tranche of approximately $3.0 million from National Institutes of Health Grant for development of OPNT003, nasal nalmefene, for treatment of opioid overdose
  • Mar 25, 2019: INSYS Therapeutics to present poster of pharmacokinetic study of Naloxone novel nasal spray at The College on Problems of Drug Dependence Annual Scientific Meeting
  • Mar 14, 2019: Adamis Pharmaceuticals announces FDA acceptance for review of the New Drug Application of its higher dose naloxone injection product candidate

Companies Mentioned

  • Adamis Pharmaceuticals Corp
  • Adapt Pharma Ltd
  • Amphastar Pharmaceuticals Inc
  • Crossject SA
  • Fab'entech SA
  • Icure Pharmaceutical Inc
  • Insys Therapeutics Inc
  • iQure Pharma Inc
  • Klaria Pharma Holding AB
  • Mucodel Pharma LLC
  • Opiant Pharmaceuticals Inc
  • Orexo AB
  • PledPharma AB
  • ResQ Pharma Inc
  • Worphmed Srl

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/twggh5

View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005421/en/